[SCHEDULE 13G] Myriad Genetics Inc SEC Filing

Rhea-AI Filing Summary

Barclays PLC reported beneficial ownership of 4,899,951 shares of Myriad Genetics common stock, equal to 5.31% of the class. The filing shows Barclays has sole voting and dispositive power over 4,762,680 shares and shared voting and dispositive power over 137,271 shares. The reporting person is classified as HC and the filing identifies related subsidiaries as Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.

This document is a Schedule 13G disclosure and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence the control of the issuer.

Positive

• Material disclosed stake: Barclays PLC beneficially owns 4,899,951 shares, representing 5.31% of Myriad Genetics common stock.
• Clear voting/dispositive control figures: Sole voting and dispositive power reported for 4,762,680 shares and shared power for 137,271 shares.

Negative

• None.

Insights

Financial Analyst

TL;DR: Barclays holds a material 5.31% stake in Myriad Genetics with substantial sole voting and dispositive power.

The filing reports 4,899,951 shares beneficially owned representing 5.31% of the class. Of those, Barclays reports sole voting and dispositive power over 4,762,680 shares and shared power over 137,271 shares. As a Schedule 13G, the statement emphasizes ordinary-course holding rather than an intent to influence control, with the reporting person classified as HC and related subsidiaries identified. For investors, the entry of a large financial institution as a >5% holder is a material ownership disclosure but the filing expressly disclaims a control purpose.

Corporate Governance Expert

TL;DR: Disclosure shows a significant institutional stake but includes a certification denying intent to alter issuer control.

The Schedule 13G lists Barclays PLC as beneficial owner of 4,899,951 shares (5.31%) and identifies subsidiaries involved in the holding. The filing includes explicit certification language that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The reporting-person classification HC and the voting/dispositive figures are clearly stated, enabling governance analysis based on exact ownership and control metrics provided in this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MYRIAD GENETICS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

62855J104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 62855J104

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,762,680.00
6	Shared Voting Power 137,271.00
7	Sole Dispositive Power 4,762,680.00
8	Shared Dispositive Power 137,271.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,899,951.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.31 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MYRIAD GENETICS INC
(b)	Address of issuer's principal executive offices: 322 North 2200 West, UT, 84116
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP No.: 62855J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4899951
(b)	Percent of class: 5.31 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4762680
	(ii) Shared power to vote or to direct the vote: 137271
	(iii) Sole power to dispose or to direct the disposition of: 4762680
	(iv) Shared power to dispose or to direct the disposition of: 137271
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	08/12/2025

FAQ

How many Myriad Genetics (MYGN) shares does Barclays PLC beneficially own?

Barclays PLC beneficially owns 4,899,951 shares of Myriad Genetics common stock.

What percentage of MYGN does Barclays' stake represent?

The reported ownership represents 5.31% of Myriad Genetics' common stock class.

How much voting power does Barclays report for its MYGN holdings?

Barclays reports sole voting power over 4,762,680 shares and shared voting power over 137,271 shares.

Is the Barclays stake reported as intended to influence control of Myriad Genetics (MYGN)?

No. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.

Which Barclays entities are identified in the Schedule 13G for this holding?

The filing identifies related subsidiaries: Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.

What type of SEC filing reports this ownership?

This ownership is reported on a Schedule 13G disclosure for common stock (CUSIP 62855J104).